-
1.发明申请Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors 审中-公开使用放射性治疗和细胞周期抑制剂的组合治疗疾病的组合物和方法公开(公告)号：US20080058579A1
公开(公告)日：2008-03-06
申请号：US11594022
申请日：2006-11-06
申请人： William Hunter , David Gravett , Richard Liggins , Troy Loss , Arpita Maiti , Philip Toleikis
发明人： William Hunter , David Gravett , Richard Liggins , Troy Loss , Arpita Maiti , Philip Toleikis
IPC分类号： A61M36/12
CPC分类号： A61N5/1027 , A61K41/0038 , A61K49/0002 , A61K49/222 , A61K51/1282 , A61L31/18 , A61N2005/1019 , A61N2005/1023 , A61K2300/00
摘要： Disclosed herein are therapeutic devices, compositions and methods for treating proliferative diseases. For example, within one aspect of the invention therapeutic devices are provided, comprising a device that locally administers radiation and a cell-cycle inhibitor
摘要翻译： 本文公开了治疗增殖性疾病的治疗装置，组合物和方法。 例如，在本发明的一个方面，提供治疗装置，其包括局部施用辐射的装置和细胞周期抑制剂
-
公开(公告)号：US20050209666A1
公开(公告)日：2005-09-22
申请号：US11006885
申请日：2004-12-07
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti
IPC分类号： A61B5/00 , A61F2/00 , A61F2/02 , A61F2/12 , A61F2/28 , A61F13/00 , A61K9/22 , A61K38/17 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M31/00 , A61N1/00 , A61N1/05 , A61N1/18 , A61N1/36 , A61N1/372 , A61N1/375
CPC分类号： A61N1/05 , A61K38/17 , A61L27/3641 , A61L27/54 , A61L31/16 , A61L2300/404 , A61L2300/416 , A61L2300/432 , A61L2300/45 , A61N1/36 , A61N1/372
摘要： Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.
-
公开(公告)号：US20050209664A1
公开(公告)日：2005-09-22
申请号：US10998349
申请日：2004-11-26
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti
CPC分类号： A61L31/10 , A61L31/16 , A61L2300/404 , A61L2300/416 , A61L2300/432 , A61N1/3605 , A61N1/372 , C08L89/00 , C08L31/04 , C08L75/04
摘要： Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.
-
公开(公告)号：US20050196421A1
公开(公告)日：2005-09-08
申请号：US11001417
申请日：2004-12-01
申请人： William Hunter , Philip Toleikis , David Gravett , Arpita Maiti , Richard Liggins , Aniko Takacs-Cox , Rui Avelar , Troy Loss
发明人： William Hunter , Philip Toleikis , David Gravett , Arpita Maiti , Richard Liggins , Aniko Takacs-Cox , Rui Avelar , Troy Loss
IPC分类号： A61B19/00 , A61F2/00 , A61F2/08 , A61F2/28 , A61F2/44 , A61K9/14 , A61K31/337 , A61K31/365 , A61K31/4745 , A61K31/704 , A61K31/7048 , A61K31/7072 , A61K38/00 , A61L27/54 , A61L31/16 , A61M31/00 , A61N1/00 , A61N1/05
CPC分类号： A61K45/06 , A61L27/54 , A61L31/16 , A61L2300/404 , A61L2300/416 , A61L2300/432
摘要： Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.
-
公开(公告)号：US20050187639A1
公开(公告)日：2005-08-25
申请号：US11006892
申请日：2004-12-07
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti
IPC分类号： A61B5/00 , A61F2/00 , A61F2/02 , A61F2/12 , A61F2/28 , A61F13/00 , A61K9/22 , A61K38/17 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M31/00 , A61N1/00 , A61N1/05 , A61N1/18 , A61N1/36 , A61N1/372 , A61N1/375
CPC分类号： A61N1/05 , A61K38/17 , A61L27/3641 , A61L27/54 , A61L31/16 , A61L2300/404 , A61L2300/416 , A61L2300/432 , A61L2300/45 , A61N1/36 , A61N1/372
摘要： Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.
-
公开(公告)号：US20050187140A1
公开(公告)日：2005-08-25
申请号：US11000408
申请日：2004-11-29
申请人： William Hunter , Philip Toleikis , David Gravett , Arpita Maiti , Richard Liggins , Aniko Takacs-Cox , Rui Avelar , Troy Loss
发明人： William Hunter , Philip Toleikis , David Gravett , Arpita Maiti , Richard Liggins , Aniko Takacs-Cox , Rui Avelar , Troy Loss
IPC分类号： A61B19/00 , A61F2/00 , A61F2/08 , A61F2/28 , A61F2/44 , A61K9/14 , A61K31/337 , A61K31/365 , A61K31/4745 , A61K31/704 , A61K31/7048 , A61K31/7072 , A61K38/00 , A61L27/54 , A61L31/16 , A61M31/00 , A61N1/00 , A61N1/05
CPC分类号： A61K45/06 , A61L27/54 , A61L31/16 , A61L2300/404 , A61L2300/416 , A61L2300/432
摘要： Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.
-
公开(公告)号：US20050182469A1
公开(公告)日：2005-08-18
申请号：US11007837
申请日：2004-12-07
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti
IPC分类号： A61B5/00 , A61F2/00 , A61F2/02 , A61F2/12 , A61F2/28 , A61F13/00 , A61K9/22 , A61K38/17 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M31/00 , A61N1/00 , A61N1/05 , A61N1/18 , A61N1/36 , A61N1/372 , A61N1/375
CPC分类号： A61N1/05 , A61K38/17 , A61L27/3641 , A61L27/54 , A61L31/16 , A61L2300/404 , A61L2300/416 , A61L2300/432 , A61L2300/45 , A61N1/36 , A61N1/372
摘要： Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.
-
公开(公告)号：US20050181977A1
公开(公告)日：2005-08-18
申请号：US10986231
申请日：2004-11-10
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins
IPC分类号： A61B17/11 , A61B17/12 , A61F2/00 , A61F2/02 , A61F2/04 , A61F2/06 , A61F2/28 , A61F2/44 , A61K38/00 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M16/04 , A61M31/00 , A61N1/05 , A62B9/00
CPC分类号： A61L31/16 , A61B17/11 , A61B17/12022 , A61B17/1219 , A61F2250/0067 , A61L2300/404 , A61L2300/406 , A61L2300/416 , A61L2300/426 , A61L2300/432 , A61N1/05
摘要： Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, e.g., an antibiotic. Suitable implants include intravascular implants, a vascular graft or wrap implant, an implant for hemodialysis access, an implant that provides an anastomotic connection, ventricular assist implant, a prosthetic heart valve implant, an inferior vena cava filter implant, a peritoneal dialysis catheter implant, a central nervous system shunt, an intraocular lens, an implant for glaucoma drainage, a penile implant, an endotracheal tube, a tracheostomy tube, a gastrointestinal device, and a spinal implant.
-
公开(公告)号：US20050181005A1
公开(公告)日：2005-08-18
申请号：US11006901
申请日：2004-12-07
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti
IPC分类号： A61B5/00 , A61F2/00 , A61F2/02 , A61F2/12 , A61F2/28 , A61F13/00 , A61K9/22 , A61K38/17 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M31/00 , A61N1/00 , A61N1/05 , A61N1/18 , A61N1/36 , A61N1/372 , A61N1/375
CPC分类号： A61N1/05 , A61K38/17 , A61L27/3641 , A61L27/54 , A61L31/16 , A61L2300/404 , A61L2300/416 , A61L2300/432 , A61L2300/45 , A61N1/36 , A61N1/372
摘要： Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.
-
公开(公告)号：US20050175661A1
公开(公告)日：2005-08-11
申请号：US10999205
申请日：2004-11-29
申请人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins , Dechi Guan
发明人： William Hunter , David Gravett , Philip Toleikis , Arpita Maiti , Pierre Signore , Richard Liggins , Dechi Guan
IPC分类号： A61B17/00 , A61B17/11 , A61B17/12 , A61F2/00 , A61F2/86 , A61F13/00 , A61K38/48 , A61L27/00 , A61L27/54 , A61L31/00 , A61L31/16 , A61M29/00 , A61M31/00
CPC分类号： A61B17/12172 , A61B17/00491 , A61B17/11 , A61B17/12022 , A61B17/12045 , A61B17/12136 , A61B17/1215 , A61B17/12177 , A61B17/12186 , A61B17/1219 , A61B2017/00004 , A61F2/86 , A61F2250/0067 , A61L31/16 , A61L2300/412
摘要： Intravascular devices (e.g., stents, stent grafts, covered stents, aneurysm coils, embolic agents and drug delivery catheters and balloons) are used in combination with fibrosing agents in order to induce fibrosis that may otherwise not occur when the implant is placed within an animal or to promote fibrosis betweent the devices and the host tissues. Compositions and methods are described for use in the treatment of aneurysms and unstable arterial (vulnerable) plaque.
-
-
-
-
-
-
-
-
-
搜索结果
102 条记录 (耗时 0.167 秒)
